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Background and Scope. Early etiologic diagnosis of ischemic stroke subtype guides acute management and treatment. We aim
to evaluate if plasma biomarkers can predict stroke subtypes in the early phase from stroke onset. Methods. Plasma N-terminal
prohormone of brain natriuretic peptide (NT-proBNP), D-dimer, C-reactive protein, serum albumin, and globulin levels have been
investigated in 114 consecutive patients presenting at the emergency roomwithin 6 hours of the ischemic stroke onset. Plasma levels
of biomarkers have been correlated with stroke aetiology (based on TOAST criteria) by multivariable logistic regression analysis,
adjusted for several covariates. Results. Of the 114 patients, 34 (30%) had cardioembolic stroke, 27 (23%) atherothrombotic stroke,
19 (17%) lacunar stroke, and 34 (30%) stroke of undetermined origin. Patients with cardioembolic stroke had significantly higher
levels of NT-proBNP and lower globulin/albumin (G/A) ratio compared with the other subgroups. At multiple logistic regression
NT-proBNP > 200 pg/mL, G/A ratio > 0.70, and NIHSS score were independent predictors of cardioembolic stroke with high
accuracy of the model, either including (AUC, 0.91) or excluding (AUC, 0.84) atrial fibrillation. Conclusions. A prediction model
that includes NT-proBNP, G/A ratio, and NIHSS score can be useful for the early etiologic diagnosis of ischemic stroke.
1. Introduction
Etiological classification of acute ischemic stroke is based on
probabilistic criteria, defined by TOAST [1]. Nearly one-third
of ischemic strokes are classified as undetermined, including
those with two or more well-identified causes. A correct
assessment of aetiology is crucial for management in the
acute and subacute phases, in order to give the patient the
prompt treatment and the best prevention of early recurrence.
It has been suggested that biological markers could
be used in etiologic identification of ischemic stroke. For
example, in stroke of cardioembolic origin, levels of brain
natriuretic peptide (BNP), known to be related to severity
andmortality [2–7], have been shown to be higher than other
stroke subtypes [8, 9]. Moreover, some authors identified cut-
off values above which the predictive value for cardioembolic
stroke (CES) is very high [8–12].
The predictive value of BNP in CES is even increased
when associated with markers of thromboembolism and
heart disease, as reported by Montaner et al. [10]. In patients
with total anterior circulation syndrome, they found that a
BNP level greater than 76 pg/mL combined with a D-dimer
(DD) level greater than 0.96mcg/mL predicts nearly 90%
of all CES. The authors concluded that the identification
of a third biomarker would further increase the diagnostic
accuracy.
It is widely reported that low albumin level corre-
lates with an increased risk of cardiovascular diseases and
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atrial fibrillation (AF) [13–16]. Emerging evidence suggests
a tight relationship between some inflammatory patterns
(i.e., high fibrinogen, C-reactive protein, low albumin, and
albumin/globulin ratio) and risk of CES in patients with
nonvalvular atrial fibrillation [17–19].
The aim of this study is to evaluate the predictive value of
a panel of specific biomarkers, easy feasible in the emergency
setting, in the early assessment of stroke aetiology.
2. Methods
2.1. Patients. From December 2003 to June 2008 consecutive
patients with acute ischemic stroke, admitted to the emer-
gency department of our hospital within 6 hours from stroke
onset, were included in this study. Detailed inclusion criteria
were age of 18–90 years, presentation within 6 hours of the
onset of acute ischemic stroke, symptoms lasting more than
60minutes, NIHSS score from5 to 25, and absence of cerebral
haemorrhage at the baseline CT scan.
At the emergency department all patients underwent
thorough evaluation including clinical history (present or
past history of hypertension, atrial fibrillation, diabetes,
hyperlipidaemia, and smoking), physical and neurological
examination, and a first panel of tests such as complete blood
work, electrocardiogram (ECG), noninvasive arterial blood
pressure monitoring, chest radiography, and unenhanced CT
scan and/or angio-CT. During the following hospital stay all
patients were further investigated with a second panel of tests
including carotid and cardiac ultrasound (transthoracic and,
in case, transesophageal) and, in selected cases, MRI-MRA,
cerebral angiography, transcranial duplex (TCD), and 24 h
ECG monitoring.
2.2. Blood Biomarkers Sampling. Blood samples for specific
biomarkers determination have been collected at inclusion
in the emergency department. Samples were centrifuged at
3000 rpm for 15 minutes, and plasma was frozen and stored
at the temperature of−20∘C.Ultrasensitive C-reactive protein
(CRP), D-dimer, albumin, and globulins were assayed with
an automated latex enhanced immunoassay or colorimetric
assay with endpoint method. Plasma N-terminal prohor-
mone of brain natriuretic peptide (NT-proBNP) level was
measured using a RIA (Human RIA Kit Phoenix Pharmaceu-
ticals).
2.3. Stroke Classifications. Stroke severity was assessed by
the National Institutes of Health Stroke Scale (NIHSS)
[20]. At discharge, stroke etiologic subtypes were identified
according to the TOAST classification (Trial of Org 10172 in
Acute Stroke Treatment) [1], which distinguishes five stroke
categories: large-artery atherosclerosis or atherothrombotic,
cardioembolic, small-vessel occlusion or lacunar, undeter-
mined or cryptogenic, and other determined aetiologies (rare
causes of stroke). To determine the TOAST category all the
information available from the hospital admission was taken
into account, including the panel of tests performed during
the hospital stay.
Stroke was also classified according to the Oxfordshire
Community Stroke Project criteria (OCSP) [21], based on
clinical symptoms, location, and extent of cerebral infarction.
OCSP classification distinguishes strokes as total anterior cir-
culation infarcts (TACI), partial anterior circulation infarcts
(PACI), lacunar infarcts (LACI), and posterior circulation
infarcts (POCI). Mortality was assessed at three months.
2.4. Statistical Analysis. For descriptive statistics we used
median for nominal and ordinal variables (such as stroke
scales) and mean and standard deviation (SD) for continu-
ous variables (i.e., NT-proBNP values). Differences among
groups were assessed by chi-square test for categorical vari-
ables and Kruskal-Wallis test for continuous variables.
The optimal cut-off points of plasma NT-proBNP, D-
dimer, CRP, albumin, plasma globulin, and globulin/albumin
ratio to identify CES versus non-CESwere obtained using the
receiver operating characteristic (ROC) curves. For selected
biomarkers sensitivity and specificity for the diagnosis of
CES and their 95% Agresti-Coull confidence intervals were
calculated after the exclusion of patients with undetermined
causes. All variables were tested one by one against the
dependent variable CES; variables associated with CES at
univariate analysis were entered into a logistic regression
model and odds ratios (OR) with their 95% confidence
interval (CI) were calculated. Biomarkers were included as
dichotomous variables (0 = less than or 1 = greater than
the cut-off value), vascular territory and etiologic subtype as
nominal variable, and NIHSS score and age as continuous
variables. Goodness of fit of the multiple logistic model was
testedwith theHosmer-Lemeshow test. An equation from the
regression model was derived to calculate the probability of
cardioembolic aetiology. Statistical analyses were performed
using the Stata software, version 11.
3. Results
During the study period 114 patients fulfilled the inclusion
criteria and were included in this study. Of those, at the
end of the hospital stay, 34 (30%) were classified as having
CES, 27 (23%) having stroke of large-artery atherosclerosis,
and 19 (17%) having stroke of small artery occlusion or
lacunae. In 34 of 114 patients (30%) the diagnostic workup
was inconclusive (27 patients) or there was coexistence of two
ormore potential causes (7 patients, including 3 patients with
AF at the emergency department and subsequent evidence of
ipsilateral symptomatic stenosis) and thereforewere classified
as having stroke of undetermined cause. No one had stroke of
other determined causes.
Mean age was 71.7 (SD 12.1) years. The distribution of
demographic and vascular risk factors was similar among the
TOAST groups, except for a history of diabetes which was
more frequent in patients with large vessels atherosclerosis
(41% versus 6–12% in the other groups) and for the presence
of AF at the emergency room in patients with CES (82%
versus 10–16% in the other groups). Patients with CES were
more severely affected than all the other groups (median
NIHSS score at presentation 14 versus 6–9) and had a
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Table 1: Demographic and clinical features in 114 patients with stroke according to TOAST classification.
Cardioembolic Large-arteryatherosclerosis
Small-vessel
occlusion
(lacune)
Undetermined aetiology
𝑃 value∗
𝑛 = 34 𝑛 = 27 𝑛 = 19 𝑛 = 34
Demographics
Females 12 (35%) 15 (56%) 11 (58%) 13 (38%) 0.22Males 22 (65%) 12 (44%) 8 (42%) 21 (62%)
Age, mean (SD) 75.9 (8) 74.1 (9) 69.8 (13.7) 71.3 (14) 0.50
History
Smoking 5 (15%) 7 (26%) 7 (37%) 7 (21%) 0.30
Hypertension 26 (76%) 23 (85%) 15 (79%) 24 (71%) 0.60
Dyslipidaemia 21 (62%) 17 (63%) 10 (52%) 15 (44%) 0.39
Diabetes 4 (12%) 11 (41%) 2 (10%) 2 (6%) 0.002
Previous stroke 8 (23%) 11 (41%) 2 (10%) 4 (12%) 0.03
Event
Atrial fibrillation at the ER admission 28 (82%)∗∗ 4 (15%) 3 (16%) 3 (9%) <0.001
Left atrial enlargement∗∗∗ 15 (56%) 8 (40%) 3 (19%) 7 (28%) 0.07
Baseline NIHSS score, median (𝑄1–𝑄3) 14.0 (9.0–19.0) 9.0 (6.0–16.0) 6.0 (5.0–7.0) 7.5 (6.0–13.0) 0.0001
3-month mortality 10 (29%) 7 (26%) 1 (5%) 1 (12%) 0.08
Location∗∗∗∗
Lacunar infarct (LACI) 2 (6%) 10 (37%) 18 (95%) 2 (6%)
<0.001Partial anterior circulation infarct (PACI) 9 (26%) 8 (30%) 1 (5%) 20 (59%)
Total anterior circulation infarct (TACI) 23 (68%) 8 (30%) 0 (0%) 9 (26%)
Posterior circulation infarct (POCI) 0 (0%) 1 (3.7) 0 (0%) 3 (9%)
Abbreviations:𝑄1: first quartile;𝑄3: third quartile; SD: standard deviation; ED: emergency department.
∗From chi-square (categorical) or Kruskal-Wallis test (continuous variables).
∗∗Of the six patients with CES without AF at the emergency department, one had an echocardiographic finding of thrombus in the left atrium and five had
developed AF during the hospital stay.
∗∗∗Based on 88 (27, 20, 16, and 25) US echocardiographic examinations.
∗∗∗∗According to Oxford Community Stroke Project (OCSP) classifications.
Table 2: Biomarker distribution in 114 patients according to TOAST classification.
Cardioembolic Large-artery atherosclerosis
Small-vessel
occlusion
(lacune)
Undetermined aetiology
𝑃 value∗
𝑛 = 34 𝑛 = 27 𝑛 = 19 𝑛 = 34
NT-proBNP (pg/mL) 254 (149–327) 137 (79–176) 86 (40–183) 117 (75–188) 0.0001
Albumin (g/mL) 3.9 (3.8–4.1) 4.1 (3.8–4.2) 4.0 (3.9–4.4) 3.9 (3.7–4.1) 0.04
Globulins (g/mL) 3.2 (2.9–3.4) 2.9 (2.8–3.3) 3.0 (2.6–3.4) 3.0 (2.7–3.3) 0.45
Globulin/albumin 0.79 (0.72–0.88) 0.74 (0.70–0.79) 0.76 (0.62–0.83) 0.77 (0.69–0.85) 0.13
CRP (𝜇g/mL) 0.48 (0.23–0.98) 0.37 (0.14–0.62) 0.43 (0.14–1.48) 0.34 (0.15–1.65) 0.44
DD (𝜇g/mL)∗∗ 406 (282–845) 408 (239–724) 304 (185–435) 308 (196–588) 0.17
All values are median (first and third quartile).
∗From chi-square (categorical) or Kruskal-Wallis test (continuous variables).
∗∗Determinations made on 101 (31, 23, 17, and 30) US echocardiographic examinations.
higher short term mortality rate (Table 1). Stroke subtypes
according to TOAST and Oxfordshire Community Stroke
Project classifications are reported in Table 1.
3.1. Biomarkers. Baseline blood samples were collected at a
median time from stroke onset of 240minutes (Q1 41–Q3 340
minutes). As shown in Table 2, the highest NT-proBNP value
was observed in CES, and the lowest in patients with lacunar
stroke. Albumin level was higher among patients with large-
artery atherosclerosis than other groups, and the G/A ratio
was higher inCES than other groups. Biomarkers that showed
a significant association with CES were NT-proBNP and G/A
ratio.
For these biomarkers, the optimal cut-off value for dis-
criminating the presence of a cardioembolic source was a
level of NT-proBNP of 200 pg/mL and a ratio of G/A of
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Table 3: Results of multiple logistic regression model for the likelihood of a stroke of cardioembolic origin among 114 patients. Odds ratios
(OR) and 95% confidence intervals (95% CI) are estimated frommultiple logistic regressionmodels including and excluding atrial fibrillation
(AF).
Cardioembolic stroke Model with AF Model without AF
No Yes OR∗ 95% CI 𝑃 value OR∗ 95% CI 𝑃 value
Sex
Female 39 12 1.00 Reference 1.00 Reference
Male 41 22 1.31 0.38–4.54 0.67 1.36 0.47–3.93 0.57
Age (years) 80 34 0.96 0.90–1.02 0.16 1.00 0.95–1.05 0.92
Baseline NIHSS score 80 34 1.10 0.99–1.22 0.09 1.14 1.04–1.24 0.005
NT-proBNP (pg/mL)
<200 66 12 1.0 Reference 1.0 Reference
≥200 14 22 3.96 1.02–15.36 0.047 5.90 2.03–17.14 0.01
Globulin/albumin
<0.70 25 3 1.0 Reference 1.0 Reference
≥0.70 55 31 3.84 0.70–20.98 0.12 4.13 1.00–17.06 0.05
Atrial fibrillation
No 70 6 1.00 Reference
Yes 10 28 24.67 6.46–94.22 <0.001
Area under ROC curve 0.91 0.84
∗Each variable is adjusted for the others.
0.7. Using this cut-off values we calculate sensitivity and
specificity of 0.65 (95% CI 0.48–0.79) and 0.82 (95% CI 0.73–
0.89) for NT-proBNP and 0.91 (95% CI 0.76–0.98) and 0.31
(95% CI 0.22–0.42) for G/A ratio.
3.2. BioclinicalModel for CES. When biomarkers that showed
a significant association with CES (A/G ratio and NT-
proBNP) were evaluated in amultivariable logistic regression
model including the baseline clinical characteristics, the
strongest predictors of a stroke of cardioembolic origin were
the presence of atrial fibrillation (OR 24.67, 95% CI 6.46–
94.22), NT-proBNP levels above 200 pg/mL (OR 3.96, 95%
CI 1.02–15.36), G/A ratio above 0.7 (OR 3.87, 95% CI 0.70–
20.98), and NIHSS score (OR for each unit increase 1.10,
95% CI 0.99–1.22) (Table 3). Since in the clinical practice the
diagnosis of cardioembolic stroke is strongly related to the
presence ofAF,we repeated the analysis after excluding it, and
results for BNP levels, NIHSS score, and globulin/albumin
ratio were even stronger. Figure 1 shows the ROC curves
corresponding to the two regressionmodels with andwithout
AF. The areas under the curve (AUCs) were good for both
models (0.91 with AF and 0.84 without AF).
The regression equations obtained were the following:
(1) withAF: log(odds) =−1.91 + 0.27× SEX-0.04×AGE +
0.09×NIHSS+ 1.38×NT-proBNP+ 1.35×G/A+ 3.21
× AF;
(2) without AF: log(odds) = −4.19 + 0.31 × SEX-0.02 ×
AGE + 0.12 × NIHSS + 1.77 × NT-proBNP + 1.42 ×
G/A.
The application of model 1 to the undetermined aetiology
group allowed the identification of 4 patients (4/34, 12%)with
probability of CES between 70 and 90%. Of those, only one
patient presented at the emergency department with AF.
4. Discussion
We found thatNT-proBNP andG/A ratio are good predictors
of CES in the early phase of diagnostic workup and they can
increase the prediction accuracy for CES of the clinical signs
alone, such as AF and event’s severity.
An early stroke classification is important for therapeutic
choices and for improving outcome. Among the different
etiologic subtypes, CES is associated with higher risk of early
recurrences; therefore, its prompt identificationmay improve
patient’s prognosis. Several studies evaluated laboratory and
clinical predictors of CES. A good association was observed
betweenCES andBNP levels [4], and an even stronger predic-
tive value was found when BNPmeasurement was combined
with D-dimer and clinical syndrome of the anterior cerebral
circulation [10]. Based on this literature evidence, we tried
to define another feasible clinical-biochemical stroke profile,
using blood tests promptly available in our emergency labo-
ratory.
BNP is released primarily from cardiac ventricles in
response to volume and pressure overload. It could be a
biomarker of ventricular dysfunction and AF [22, 23] and
its increase could be related to blood stasis, which is a well-
known condition for thrombi formation and risk of embolism
[24, 25]. The peptide and its terminal fragment NT-proBNP
were found elevated in patients with acute ischemic stroke,
and their plasma level was associated with stroke severity
and mortality [3, 5, 6]; in addition, increased BNP levels are
suggestive of a cardioembolic source for the cerebrovascular
event [7–10, 12]. In our study, BNP alone showed sensitivity
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Figure 1: Receiver operating characteristic (ROC) curves for selected clinical variables among 114 patients (34 with cardioembolic stroke and
80 with stroke of other origins), alone or in combination in multiple logistic regression models. (a) Model with atrial fibrillation; (b) model
without atrial fibrillation. See Table 3 for model specification.
for CES definition of 65% and a positive predictive value of
61%, which is in line with other series reports [25].
It is widely accepted that inflammation represents a risk
factor for AF and for prothrombotic conditions [24–27].
Different molecules behave differently during an inflam-
matory phase; albumin synthesis decreases, while other
inflammatory globulins rise (i.e., fibrinogen, CRP, alpha-2-
macroglobulin, etc.). This pattern is regulated by circulating
cytokines, mostly IL-6. Albumin and globulins variations
could also be suggestive of a prothrombotic state [17], and
globulin/albumin ratio (G/A) correlates with blood viscosity,
being a high ratio associated with increased blood viscosity.
Our results support the hypothesis that specific biomark-
ers could be a useful tool for early identification of stroke
subtypes, mainly CES. We identified a “cardioembolic pat-
tern” that includes stroke severity, BNP > 200 pg/mL and
G/A ratio > 0.7, which was a good predictor of CES, reaching
an accuracy of nearly 90%. These findings confirm previous
literature data [7, 28, 29], supporting the suggestion that
the combination of clinical and biochemical variables leads
to a better definition of stroke aetiology. Differently from
Montaner et al., who identified BNP and D-dimer as good
predictors of CES, in our series D-dimer turned out not to be
as good as G/A ratio in predicting CES.
Ourmodel is easily applicable in the emergency roomand
can be useful for the identification of patients with a stroke
profile at high risk for early recurrence and unfavourable
outcome such as CES.
Limitations of our study are the small number of the
patient’s series and the slow recruitment rate. All patients
were recruitedwithin 6 hours from stroke onset and therefore
represent a peculiar stroke patient population. This may
have implied a higher proportion of CES compared to other
series because CES is usually characterized by abrupt onset
causing the patient to reach medical attention more quickly.
The high proportion of CES, however, did not affect the
results of our analysis. Moreover, in the common practice,
etiologic classifications are limited by the lack of a clear cut
definition of ischemic stroke in the undetermined category,
where patients with cardioembolic causes are also included.
To overcome this issue, a new phenotype-based classification,
the A-S-C-O system, was developed few years ago [30]. This
system, different from the TOAST classification that consid-
ers only the most likely cause(s) of stroke, aims to better
describe the phenotype of the patients and the aetiology
of the stroke, without neglecting the information. However,
the recruitment and the data collection took place before
the publication of the A-S-C-O stroke classification system;
therefore, a direct comparison with the proposed bioclinical
model was not possible.
5. Conclusions
NT-proBNP, albumin, and globulin are useful for early diag-
nosis of CES; the increase of NT-proBNP over 200 pg/mL,
G/A ratio > 0.7, with or without AF and in presence of
severe stroke, supports the suspicion of cardioembolism. We
think that the identification of a specific clinical-biochemical
profile could help in the emergency setting to better address
the most appropriate instrumental diagnostic workup in
selected patients with ischemic stroke.
6 Emergency Medicine International
Conflict of Interests
The authors declare that there is no conflict of interests regar-
ding the publication of this paper.
Acknowledgment
Theauthors thankValterMonzani, DepartmentChairperson,
who provided general support.
References
[1] H. P. Adams Jr., B. H. Bendixen, L. J. Kappelle et al., “Classifica-
tion of subtype of acute ischemic stroke: definitions for use in a
multicenter clinical trial,” Stroke, vol. 24, no. 1, pp. 35–41, 1993.
[2] J. K. Jensen, D. Atar, S. R. Kristensen, H. Mickley, and J. L. Jan-
uzzi Jr., “Usefulness of natriuretic peptide testing for long-term
risk assessment following acute ischemic stroke,”The American
Journal of Cardiology, vol. 104, no. 2, pp. 287–291, 2009.
[3] A.M.Ma¨kikallio, T. H.Ma¨kikallio, J. T. Korpelainen et al., “Nat-
riuretic peptides and mortality after stroke,” Stroke, vol. 36, no.
5, pp. 1016–1020, 2005.
[4] J. Montaner, T. Garcia-Berrocoso, M. Mendioroz et al., “Brain
natriuretic peptide is associated with worsening and mortality
in acute stroke patients but adds no prognostic value to clinical
predictors of outcome,” Cerebrovascular Diseases, vol. 34, pp.
240–245, 2012.
[5] K. Nakagawa, T. Yamaguchi, M. Seida et al., “Plasma concentra-
tions of brain natriuretic peptide in patients with acute ischemic
stroke,” Cerebrovascular Diseases, vol. 19, no. 3, pp. 157–164,
2005.
[6] H. Tomita, N. Metoki, G. Saitoh et al., “Elevated plasma brain
natriuretic peptide levels independent of heart disease in acute
ischemic stroke: correlation with stroke severity,” Hypertension
Research, vol. 31, no. 9, pp. 1695–1702, 2008.
[7] W.Whiteley, J.Wardlaw,M.Dennis et al., “Blood biomarkers for
the diagnosis of acute cerebrovascular diseases: a prospective
cohort study,” Cerebrovascular Diseases, vol. 32, no. 2, pp. 141–
147, 2011.
[8] K. Shibazaki, K. Kimura, Y. Iguchi, Y. Okada, and T. Inoue,
“Plasma brain natriuretic peptide can be a biological marker
to distinguish cardioembolic stroke from other stroke types in
acute ischemic stroke,” InternalMedicine, vol. 48, no. 5, pp. 259–
264, 2009.
[9] K. Yukiiri, N. Hosomi, T. Naya et al., “Plasma brain natriuretic
peptide as a surrogate marker for cardioembolic stroke,” BMC
Neurology, vol. 8, article 45, 2008.
[10] J. Montaner, M. Perea-Gainza, P. Delgado et al., “Etiologic
diagnosis of ischemic stroke subtypes with plasma biomarkers,”
Stroke, vol. 39, no. 8, pp. 2280–2287, 2008.
[11] T. Naya, K. Yukiiri, N. Hosomi et al., “Brain natriuretic peptide
as a surrogatemarker for cardioembolic strokewith paroxysmal
atrial fibrillation,” Cerebrovascular Diseases, vol. 26, no. 4, pp.
434–440, 2008.
[12] M. Rodr´ıguez-Ya´ez, T. Sobrino, M. Blanco et al., “High serum
levels of pro-brain natriuretic peptide (pro BNP) identify card-
ioembolic origin in undetermined stroke,”DiseaseMarkers, vol.
26, no. 4, pp. 189–195, 2009.
[13] J. Danesh, R. Collins, P. Appleby, and R. Peto, “Association of
fibrinogen, C-reactive protein, albumin, or leukocyte count
with coronary heart disease: meta-analyses of prospective
studies,” Journal of the American Medical Association, vol. 279,
no. 18, pp. 1477–1482, 1998.
[14] L. Djousse´, K. J. Rothman, L. A. Cupples, D. Levy, and R. C.
Ellison, “Serum albumin and risk of myocardial infarction and
all-cause mortality in the framingham offspring study,” Circula-
tion, vol. 106, no. 23, pp. 2919–2924, 2002.
[15] K. J. Mukamal, J. S. Tolstrup, J. Friberg, M. Grønbaek, and G.
Jensen, “Fibrinogen and albumin levels and risk of atrial fibri-
llation in men and women (the copenhagen city heart study),”
The American Journal of Cardiology, vol. 98, no. 1, pp. 75–81,
2006.
[16] R. F. Gillum, D. D. Ingram, and D. M. Makuc, “Relation bet-
ween serum albumin concentration and stroke incidence and
death: the NHANES I epidemiologic follow-up study,” Ameri-
can Journal of Epidemiology, vol. 140, no. 10, pp. 876–888, 1994.
[17] F. J. Alvarez-Perez, M. Castelo-Branco, and J. Alvarez-Sabin,
“Usefulness of measurement of fibrinogen, D-dimer, D-
dimer/fibrinogen ratio, C reactive protein and erythrocyte sed-
imentation rate to assess the pathophysiology and mechanism
of ischaemic stroke,” Journal of Neurology, Neurosurgery and
Psychiatry, vol. 82, no. 9, pp. 986–992, 2011.
[18] D. S. G. Conway, P. Buggins, E. Hughes, and G. Y. H. Lip, “Rela-
tionship of interleukin-6 and C-reactive protein to the pro-
thrombotic state in chronic atrial fibrillation,” Journal of the
American College of Cardiology, vol. 43, no. 11, pp. 2075–2082,
2004.
[19] D. S. G. Conway, P. Buggins, E. Hughes, and G. Y. H. Lip, “Prog-
nostic significance of raised plasma levels of interleukin-6 and
C-reactive protein in atrial fibrillation,”AmericanHeart Journal,
vol. 148, no. 3, pp. 462–466, 2004.
[20] L. B. Goldstein and G. P. Samsa, “Reliability of the National
Institutes of Health Stroke Scale: extension to non-neurologists
in the context of a clinical trial,” Stroke, vol. 28, no. 2, pp. 307–
310, 1997.
[21] J. Bamford, P. Sandercock, M. Dennis, J. Burn, and C. Warlow,
“Classification and natural history of clinical identifiable sub-
types of cerebral infarction,” The Lancet, vol. 337, no. 8756, pp.
1521–1526, 1991.
[22] N. C. Davidson, A. A. Naas, J. K. Hanson, N. S. J. Kennedy, W. J.
Coutie, and A. D. Struthers, “Comparison of atrial natriuretic
peptide, B-type natriuretic peptide, and N-termmal proatrial
natriuretic peptide as indicators of left ventricular systolic
dysfunction,” The American Journal of Cardiology, vol. 77, no.
10, pp. 828–831, 1996.
[23] T. Omland, A. Aakvaag, and H. Vik-Mo, “Plasma cardiac
natriuretic peptide determination as a screening test for the
detection of patients with mild left ventricular impairment,”
Heart, vol. 76, no. 3, pp. 232–237, 1996.
[24] E. Cecchi, R. Marcucci, D. Poli et al., “Hyperviscosity as a pos-
sible risk factor for cerebral ischemic complications in atrial fib-
rillation patients,” The American Journal of Cardiology, vol. 97,
no. 12, pp. 1745–1748, 2006.
[25] S. Kurl,M.Ala-Kopsala,H. Ruskoaho et al., “PlasmaN-terminal
fragments of natriuretic peptides predict the risk of stroke and
atrial fibrillation in men,” Heart, vol. 95, no. 13, pp. 1067–1071,
2009.
[26] M. K. Chung, D. O. Martin, D. Sprecher et al., “C-reactive pro-
tein elevation in patients with atrial arrhythmias: inflammatory
mechanisms and persistence of atrial fibrillation,” Circulation,
vol. 104, no. 24, pp. 2886–2891, 2001.
[27] S. Kamath, A. D. Blann, B. S. P. Chin, and G. Y. H. Lip, “Platelet
activation, haemorheology and thrombogenesis in acute atrial
Emergency Medicine International 7
fibrillation: a comparison with permanent atrial fibrillation,”
Heart, vol. 89, no. 9, pp. 1093–1095, 2003.
[28] B. M. Coull, N. Beamer, P. de Garmo et al., “Chronic blood hyp-
erviscosity in subjects with acute stroke, transient ischemic att-
ack, and risk factors for stroke,” Stroke, vol. 22, no. 2, pp. 162–
168, 1991.
[29] T. Garc´ıa-Berrocoso, I. Ferna´ndez-Cadenas, P. Delgado, A. Ro-
sell, and J. Montaner, “Blood biomarkers in cardioembolic stro-
ke,” Current Cardiology Reviews, vol. 6, no. 3, pp. 194–201, 2010.
[30] P. Amarenco, J. Bogousslavsky, L. R. Caplan, G. A. Donnan, and
M. G. Hennerici, “New approach to stroke subtyping: the A-
S-C-O (phenotypic) classification of stroke,” Cerebrovascular
Diseases, vol. 27, no. 5, pp. 502–508, 2009.
Submit your manuscripts at
http://www.hindawi.com
Stem Cells
International
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
MEDIATORS
INFLAMMATION
of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Behavioural 
Neurology
Endocrinology
International Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Disease Markers
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
BioMed 
Research International
Oncology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Oxidative Medicine and 
Cellular Longevity
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
PPAR Research
The Scientific 
World Journal
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2014
Immunology Research
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Journal of
Obesity
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
 Computational and  
Mathematical Methods 
in Medicine
Ophthalmology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Diabetes Research
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Research and Treatment
AIDS
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Gastroenterology 
Research and Practice
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Parkinson’s 
Disease
Evidence-Based 
Complementary and 
Alternative Medicine
Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com
